NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/20/2025
Back to search
Official data from USPTO
MILYNVO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
16
Latest update
05/20/2025
Trademark type
Combined
Nice classes
5, 10
Filing date
01/23/2024
Registration date
05/20/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/20/2025
Last transaction
05/20/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
3
Owner type
03
Owner location
Palma de Mallorca (Isl, ES
Examiner
JOHNSON, KAREINE
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the word "MILYNVO" with an array of dots arranged in a wave shape above the letter "O" and extending to the right of the letter "O" with smaller dots being disposed in a central part of the array and larger dots at opposite left and right ends of the array.
Holders and representatives
Holders
L. A. (pessoa física)
Representatives
Gerald E. Hespos Hespos & Porco LLP
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical compositionspreparations for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Pharmaceutical drugspreparations for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Medicines for human purposes for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Medicines for veterinary purposes for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Pomades for medical purposes; Skin care preparations for medical use; Pharmaceutical preparations for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Herbal preparations for medical use; Nutraceutical preparations for therapeutic or medical purposes; Medicinal preparations and diagnostic substances for medical purposes; Pharmaceutical preparations and diagnostic substances for medical purposes; Veterinary preparations and diagnostic substances for medical purposes; Dietary supplements and dietetic preparations adapted for medical purposes; Natural remedies preparations for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Greases for medical or veterinary purposes; Animal fodder additives in the nature of acidifiers and enzymes for medical purposes; Additives in the nature of dietary supplements for animals; Dietary supplements for animals; Dietary supplements for human beings; Cardiovascular agents for medical purposes; Cellular function activating agents for medical purposes; Cachets for medicinal purposesantivirals and capsules for pharmaceutical purposes; Biological preparations for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Bacteriological preparations for medical and veterinary use; Biochemical preparations for medical usebioengineered membranes for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Biochemical preparations for veterinary usebioengineered membranes for the treatment of cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Reagents for medical use; Diagnostic preparations for medical or veterinary purposes; Biological reagents for medical use; Clinical medical reagents; Medical diagnostic reagents for the analysis of body fluids; Reagents for veterinary purposes for the analysis of body fluids; Diagnostic reagents for medical or veterinary purposes; Medical diagnostic reactants for medical diagnosis of disease; Reagents for use in diagnostic tests for medical purposes; Pharmaceutical compounds for treating cancer; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations and substances for the prevention of cancer; Pharmacological preparations for skincare; Pharmaceutical preparations for the treatment of disorders of the metabolic system; Pharmaceutical preparations for the treatment of diseases of the nervous system; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical agents for treating physically caused lesions; Probioticvitamin and mineral preparations in powder formfor medical use; Diagnostic and analytical kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detectioncancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosisfor medical use or for veterinary purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of human and animal bodily fluids for medical purposes or for veterinary purposes; Diagnostic and analytical kits comprising diagnostic agentspreparations and substances for medical use; Diagnostic kits comprised primarily of medical diagnostic reagentsfor medical use; Diagnostic kits comprised primarily of chemical reagent preparations for medical or veterinary use; Diagnostic test kits for medical diagnosis purposes consisting primarily of reagents for use in detecting diseases in humans and animals.
Class 10
Applicators for medicationssyringesnebulizersspoons for administering medicine and medicinal catheters; Receptacles for applying medicinespowder and liquid mixer cups for dispensing medicinedosage dispensers for administering medicine to patientsdropper bottles for administering medicationsold empty and medicine dispensing kit comprised primarily of powder and liquid mixer cups for dispensing medicine and a dosage dispenser for administering medicine to patients; Injection devices for pharmaceuticals; Drug delivery devices sold emptysyringes and infusion sets; Diagnostic apparatus for medical purposes used in medical laboratories for testing blood sugar levelscancer cellsDNARNAbody fluids; tools for medical diagnosticsmedical diagnostic instruments for testing blood sugar levelscancer cellsDNARNAbody fluids; Medical diagnostic apparatus for measuring blood sugar levelscancer cellsDNARNAbody fluids; Diagnostic apparatus for use in medical procedures for testing blood sugar levelscancer cellsDNARNAbody fluids; Testing apparatus for medical purposes; Test probe assemblies for medical use; Test probes for medical use; Testing instruments for medical diagnostic purposesfor blood sugar levelscancer cellsDNARNAbody fluids; Testing probes for medical diagnostic purposesprobes for cancervascular pathologiesobesityhypertensioncutaneous pathologiesmetabolic pathologiescardiovascular diseasesinflammatory diseasessystemic diseasesrespiratory diseasesinfectious pathologiesnerve fibre lesionsneurodegenerative pathologiesincluding Alzheimerneuroregenerationneurological diseasesneuropathic painparalysissleep disordersdigestive pathologiesmusculoskeletal and connective tissue diseasesgenitourinary pathologieshypercholesterolemiahypertriglyceridemia and cystic fibrosis; Medical and diagnostic medical instrument kits for medical diagnosis purposes consisting primarily of probesbuffers and reagents for use in microbial testing.
Publications
History of USPTO decisions and trademark events.
16 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
05/20/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/01/2025
PUBO
PUBLISHED FOR OPPOSITION
04/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/26/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/15/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/15/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/15/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/03/2024
GNRT
NON-FINAL ACTION E-MAILED
10/03/2024
CNRT
NON-FINAL ACTION WRITTEN
10/03/2024
DOCK
ASSIGNED TO EXAMINER
08/19/2024
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
05/24/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/24/2024
NWAP
NEW APPLICATION ENTERED
01/23/2024
Continuous trademark protection
Get notified about every new filing that threatens MILYNVO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.